Akademik Veri Yönetim Sistemi
Coordination Chemistry Reviews, cilt.559, 2026 (SCI-Expanded, Scopus)
Discrimination of the malignant tissue from that of healthy one requires rationally designed therapeutics, probes or theranostic devices. This challenge is addressed by scientists of different disciplines, i.e. medicinal chemists, chemical biologists, pharmacologists and many promising activatable therapeutic agents have been developed so far. Expanded knowledge on the molecular mechanisms of diseases reveals the biomarkers for many specific pathological conditions such as over-expressed enzymes, elevated metabolites, change in the redox status of the cell or its microenvironment. By incorporating the disease responsive chemical groups on the structure of therapeutics, the drug-target interaction or other functional properties of the drug can be regulated. This enables on-target activation, reduced side effects, escape from quick metabolization, longer circulation time, enhanced stability and/or better penetration through biological membranes (i.e. blood brain barrier, plasma membrane). This review focuses on the design strategies used for the development of prodrugs highlighting the recent advances in photodynamic therapy, targeted protein degradation (PROTAC), G-quadruplex stabilization and other therapeutic modalities to guide the scientists in their journey to assemble/rebuild molecular LEGOs with the intention to develop effective target activatable small molecule therapeutic agents.